GlassScriptPhysician profile
Corey Senegal
NPI 1841908035
$4,089.79
in general payments reported to CMS, 2019-2025
21 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,073 · 2024: $1,291 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,218.30 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $569.68 | 2023-2025 | |
| Novo Nordisk INC | $463.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $262.77 | 2023 | |
| Lilly USA, LLC | $238.97 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $201.26 | 2023-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.58 | 2023-2025 | Jardiance |
| Dexcom, INC. | $142.60 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Corcept Therapeutics | $135.71 | 2025 | Korlym |
| Genzyme Corporation | $121.82 | 2024 | |
| Phathom Pharmaceuticals, INC. | $120.13 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $106.96 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $86.08 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $76.58 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $34.84 | 2023-2025 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.87 | 2025 | Veozah |
| Almatica Pharma LLC | $31.68 | 2025 | Loreev Xr |
| Ardelyx, INC. | $21.85 | 2025 | Ibsrela |
| Inspire Medical Systems, INC. | $17.92 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $17.10 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Senegal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.